Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024

Press Release

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024 NEWS PROVIDED BY Alphyn Biologics Aug 27, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 27, 2024 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that data from its Phase 2a human clinical…

Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel

Press Release

Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics Aug 21, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 21, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that it has received a notice of claims allowance from the U.S. Patent and Trademark…

Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis

Press Release

Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 07, 2024, 07:30 ET All endpoints met Significant improvements in itch and quality of life Significant control of staph bacteria-associated and other AD flares Clearance of infected AD skin Significant improvements in inflammation ANNAPOLIS,…

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

Press Release

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection NEWS PROVIDED BY Alphyn Biologics Jul 14, 2023, 07:30 ET Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis ANNAPOLIS, Md. and ASHEVILLE, N.C., July 14, 2023 /PRNewswire/ — Alphyn Biologics,…

Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis

Press Release

Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Jul 10, 2023, 16:15 ET -Statistically significant improvements in IGA (Investigator Global Assessment) and EASI (Eczema Area and Severity Index) scores – Fast itch reduction by day 4 and sustained itch reduction – Body…